



PRIVATE FUNDING OPPORTUNITIES: SEP 29, 2017

Please contact Corporate & Foundation Relations in the Office of Development at devcfr@mgh.harvard.edu if you wish to submit a proposal in response to any of these opportunities. Note that proposals are still routed through the standard InfoEd/Research Management process.

Please be aware that any grant that brings in less than **15% in indirect costs (IDC)** will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

1. Global Clinical Trials Fund, Alzheimer's Research UK (ARUK)

The Global Clinical Trials Fund supports clinical trials that have potential to be of benefit to dementia patients. Lead applicants and trial sites can be from the UK or international.

The remit of this scheme covers:

- Studies that aim to demonstrate target engagement, Phase I or Phase II clinical trials undertaken to ascertain the potential safety and efficacy of (novel or re-purposed) drug-based interventions in human subjects.
- Clinical trials of non-drug based, complex interventions.
- Opportunities for research 'add ons' to ongoing clinical trials (e.g. biomarker add-ons).

This scheme is not designed to cover:

- Interventions or devices for 'assisted living' or for care management.
- Observational/biomarker clinical studies - UK-based applications covering these are acceptable through Alzheimer's Research UK's other grant schemes (for which there must be a UK-based lead applicant). However, please note that biomarker studies can be included in an application to the Global Clinical Trials Fund as primary and/or secondary outcome measures of drug action or if considered as add-ons to ongoing clinical trials.

Award Amount: Up to £1,000,000 GBP

Indirect Costs: Unspecified

Expression of Interest Deadline: Nov 15, 2017

Website: <http://www.alzheimersresearchuk.org/grants/global-clinical-trials-fund/>



Do you want to learn more about identifying external funding opportunities? See [ECOR's website](#) for information on the funding opps database, **COS Pivot** or contact Amy Robb <arobb@mgh.harvard.edu> to schedule an individual consultation or group training session.

2. Target Validation Pathfinder Grant, Alzheimer's Research UK (ARUK)

The Target Validation Pathfinder Grant scheme provides funds for small, translational research projects that show potential for an application to the Dementia Consortium or collaboration with the ARUK Drug Discovery Alliance.

Alzheimer's Research UK has developed two strategic initiatives to support the discovery of new therapeutics for dementia, covering preclinical target validation and early phase drug discovery.

The ARUK Drug Discovery Alliance (DDA) is a network of Drug Discovery Institutes (DDIs) embedded within the Universities of Cambridge, Oxford and University College London. The DDA will take advantage of new science in neurodegenerative diseases that cause dementia from within the academic Institutions and elsewhere and rapidly translate this to novel drug discovery projects and/or novel biomarkers with clinical or diagnostic utility.

The Dementia Consortium brings together ARUK, MRC Technology and five pharmaceutical companies, Abbvie, Astex, Eisai, Lilly and MSD, to support drug discovery and pharmacological validation of novel molecular targets and expedite the development of new drugs for dementia. The Dementia Consortium provides funding, resources and expertise both to increase the number of, and capitalise upon, new drug targets emerging from across the academic sector. MRC Technology is a life science medical research charity that helps bridge the gap between early stage research and commercial application through its dedicated drug discovery laboratories and 70+ scientists with expertise across early stage small molecule and antibody drug discovery. Any promising drug targets will then be made available to any of the Pharma partners.

There are both similarities and differences between the work of the Drug Discovery Alliance and the Dementia Consortium. ARUK wishes to see different options available for researchers and their individual preferences or circumstances.

It is recognised that researchers may have promising data / projects which are too preliminary to progress with either the Drug Discovery Alliance or the Dementia Consortium. The Target Validation Pathfinder grant scheme (TVPG) is designed to support translational research that shows potential for an application to the Dementia Consortium or collaboration with the ARUK Drug Discovery Alliance, but would benefit from funding for preliminary, early-stage target validation work or feasibility studies to establish the viability of an approach.

Award Amount: £50,000 GBP for 1 year

Indirect Costs: Unspecified

Application Deadline: Nov 15, 2017

Website: <http://www.alzheimersresearchuk.org/grants/target-validation-pathfinder-grant/>

3. Clinical Investigations Research Grants, American Otological Society (AOS)

AOS is committed to the non-promotional advancement of knowledge and science and to a free exchange of medical education in otology and neurotology. Research supported by all of the grant mechanisms can relate to any aspects of the ear, hearing and balance disorders.

The goal of this grants is to accrue preliminary data support an R21 or R01 clinical trial grant application.

Award Amount: \$66,000 for 1 year

Indirect Costs: 10%

LOI Deadline: Nov 1, 2017

Website: <http://www.americanotologicalsociety.org/aos-grant-submission-instructions>

4. ARRS/Leonard Berlin Scholarship in Medical Professionalism, American Roentgen Ray Society (ARRS)/Roentgen Fund

This scholarship is intended to support study and research related to medical ethics, medico-legal principles, patient accountability, sensitivity to patient diversity and/or other topics encompassing medical professionalism.

The scholarship may be used for study at or outside the scholar's parent institution, and is open to radiologists at all stages of their careers.

Award Amount: Up to \$100,000 paid over 1-2 years

Indirect Costs: None

Nomination Deadline: Nov 13, 2017

Website: <http://www.arrs.org/ARRSLIVE/BerlinScholarship>

5. Research Grants, British Society for Antimicrobial Chemotherapy (BSAC)

The BSAC's grant awarding strategy is to improve the prevention and treatment of infectious disease, and to promote the appropriate and effective use of antimicrobial agents through grant awards for research, travel and other grants to institutions and individuals.

In 2017 The BSAC is giving priority to the following research topics for Research grant applications:

1. Diagnostics
 - A. More optimal/effective use of antimicrobials through PK/PD in clinical practice
 - B. Prognostic markers of bacterial infection (i.e. When is an antibacterial indicated?)
 - C. Prognostic markers of infection with microorganisms resistant to first-line empirical treatment regimens (i.e. When is a broad-spectrum antibacterial indicated?)

- D. Can better use of existing or new laboratory diagnostics including biomarkers support better stewardship across healthcare communities, with special reference to Virology?
2. Antimicrobial Stewardship
 - A. The impact of resistance or antimicrobial consumption surveillance on patient outcomes in community, long term care and acute facilities
 - B. Innovative promotion of behaviour change science in prescribing in all healthcare settings
 - C. Impact of educational solutions/ guidelines on stewardship practice / infection treatment outcomes (could be systematic review)
 - D. Impact of sepsis campaigns on optimal antibiotic use / stewardship or use of "older agents" used in stewardship on clinical outcomes.
3. Virology: Targeting viruses with pre-existing resistance to licensed therapies
4. Antibiotic Adjuvants: Antibiotic adjuvants i.e. resistance breakers (such as efflux pump inhibitors, uptake enhancers e.g. polymyxin B nonapeptide)
5. Molecular Mechanisms Of Antimicrobial Resistance (including bacteria, fungi, parasites and viruses).

Wherever possible projects should be cross disciplinary and take account of the One Health Agenda.

Applications are also invited under the usual BSAC areas of interest:

- Mechanisms of antibacterial action
- Mechanisms of antibacterial resistance
- Antiviral resistance
- Antiviral
- Antifungals
- Antibiotic methods
- Antibiotic prescribing
- Antibiotic therapy
- Antiparasitics
- Evidence based medicine / systematic reviews.

BSAC does not currently offer co-funding of grants. When applying for any BSAC grant, all applicants must declare if they have sought, or if they intend to seek, any financial support outside of BSAC for the same grant.

Award Amount: £50,000 GBP for 1 year

Indirect Costs: Unspecified

Application Deadline: Nov 29, 2017

Website: <http://bsac.org.uk/funding/research-grants/>

6. Research Grants, Oxalosis and Hyperoxaluria Foundation (OHF)

The OHF seeks to support research that will ultimately lead to new diagnostics, treatments, and a cure for Primary Hyperoxaluria and related Hyperoxaluria conditions.

Award Amount: \$200,000 paid over 2 years

Indirect Costs: 10%

Application Deadline: Nov 1, 2017

Website: <http://ohf.org/grants-funding/>

7. TSA Research Grant and Fellowship Program, Tourette Association of America

The Tourette Syndrome Association requests research grant proposals from researchers in basic and clinical studies on all aspects of Tourette syndrome. All applications relevant to Tourette Syndrome will be considered. Applications that will enable TSA to establish the prevalence of TS and tic disorders in adults are strongly encouraged.

Award Amount: Up to \$150,000

Post-Doctoral Fellowships are funded at up to \$50,000 for one year. Research Grant Awards are funded at up to \$75,000 for one year or up to \$150,000 for two years.

Indirect Costs: 10%

Preliminary Proposal Deadline: Nov 1, 2017

Website: <https://www.tourette.org/research-medical/grants-fellowships/>

8. Grants, Weil Foundation New

The Foundation offers grants to help finance efforts to advance Integrative Medicine. These grants are usually "start-up" grants to assist medical schools and/or residency programs to develop educational programs in integrative medicine.

Integrative medicine emphasizes the innate healing capacities of the organism; views patients as mental-emotional beings, spiritual entities, and community members as well as physical bodies; addresses all aspects of lifestyle in evaluating health and illness; places great importance on the role of the practitioner-patient relationship in the healing process; and makes use of all appropriate therapies.

Award Amount: Unspecified amount for 1 year

Indirect Costs: None

Proposal Deadline: Jan 31, 2018

Website: <http://www.weilfoundation.org/grants>